Xencor Inc (XNCR) Stake Raised by Schwab Charles Investment Management Inc.
Schwab Charles Investment Management Inc. raised its holdings in Xencor Inc (NASDAQ:XNCR) by 20.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 244,491 shares of the biopharmaceutical company’s stock after buying an additional 41,617 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Xencor were worth $9,049,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Sei Investments Co. bought a new stake in shares of Xencor in the 2nd quarter worth approximately $138,000. SG Americas Securities LLC bought a new stake in shares of Xencor in the 1st quarter worth approximately $115,000. Thompson Investment Management Inc. bought a new stake in shares of Xencor in the 2nd quarter worth approximately $215,000. UBS Group AG grew its position in shares of Xencor by 449.9% in the 1st quarter. UBS Group AG now owns 5,972 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 4,886 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in shares of Xencor in the 2nd quarter worth approximately $232,000. Hedge funds and other institutional investors own 83.02% of the company’s stock.
A number of brokerages have recently weighed in on XNCR. BidaskClub upgraded Xencor from a “hold” rating to a “buy” rating in a research report on Thursday, September 20th. BTIG Research assumed coverage on Xencor in a research report on Thursday, June 7th. They set a “buy” rating and a $56.00 price target on the stock. Canaccord Genuity lifted their price target on Xencor from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded Xencor from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research report on Friday, August 10th. Finally, Piper Jaffray Companies restated an “overweight” rating on shares of Xencor in a research report on Tuesday, August 7th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $40.38.
NASDAQ XNCR opened at $43.16 on Tuesday. Xencor Inc has a twelve month low of $18.97 and a twelve month high of $48.38. The company has a market cap of $2.39 billion, a P/E ratio of -40.67 and a beta of 1.61.
Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.02. Xencor had a negative return on equity of 20.32% and a negative net margin of 137.35%. research analysts predict that Xencor Inc will post -2.24 EPS for the current fiscal year.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More: What is the NASDAQ Stock Market?
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.